全文获取类型
收费全文 | 2280篇 |
免费 | 156篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 20篇 |
儿科学 | 147篇 |
妇产科学 | 98篇 |
基础医学 | 281篇 |
口腔科学 | 74篇 |
临床医学 | 227篇 |
内科学 | 554篇 |
皮肤病学 | 54篇 |
神经病学 | 170篇 |
特种医学 | 163篇 |
外科学 | 254篇 |
综合类 | 46篇 |
一般理论 | 1篇 |
预防医学 | 160篇 |
眼科学 | 23篇 |
药学 | 102篇 |
中国医学 | 5篇 |
肿瘤学 | 75篇 |
出版年
2022年 | 15篇 |
2021年 | 46篇 |
2020年 | 41篇 |
2019年 | 54篇 |
2018年 | 59篇 |
2017年 | 50篇 |
2016年 | 54篇 |
2015年 | 59篇 |
2014年 | 57篇 |
2013年 | 97篇 |
2012年 | 115篇 |
2011年 | 136篇 |
2010年 | 119篇 |
2009年 | 83篇 |
2008年 | 120篇 |
2007年 | 120篇 |
2006年 | 95篇 |
2005年 | 88篇 |
2004年 | 68篇 |
2003年 | 62篇 |
2002年 | 57篇 |
2001年 | 59篇 |
2000年 | 52篇 |
1999年 | 42篇 |
1998年 | 59篇 |
1997年 | 51篇 |
1996年 | 43篇 |
1995年 | 32篇 |
1994年 | 40篇 |
1993年 | 37篇 |
1992年 | 27篇 |
1991年 | 20篇 |
1990年 | 18篇 |
1989年 | 34篇 |
1988年 | 29篇 |
1987年 | 37篇 |
1986年 | 25篇 |
1985年 | 23篇 |
1984年 | 15篇 |
1983年 | 20篇 |
1982年 | 15篇 |
1981年 | 12篇 |
1980年 | 19篇 |
1979年 | 11篇 |
1978年 | 14篇 |
1977年 | 23篇 |
1976年 | 16篇 |
1974年 | 9篇 |
1970年 | 9篇 |
1966年 | 9篇 |
排序方式: 共有2454条查询结果,搜索用时 31 毫秒
1.
Jennifer C. Sasaki Ashley Allemang Steven M. Bryce Laura Custer Kerry L. Dearfield Yasmin Dietz Azeddine Elhajouji Patricia A. Escobar Albert J. Fornace Jr Roland Froetschl Sheila Galloway Ulrike Hemmann Giel Hendriks Heng-Hong Li Mirjam Luijten Gladys Ouedraogo Lauren Peel Stefan Pfuhler Daniel J. Roberts Véronique Thybaud Jan van Benthem Carole L. Yauk Maik Schuler 《Environmental and molecular mutagenesis》2020,61(1):114-134
In May 2017, the Health and Environmental Sciences Institute's Genetic Toxicology Technical Committee hosted a workshop to discuss whether mode of action (MOA) investigation is enhanced through the application of the adverse outcome pathway (AOP) framework. As AOPs are a relatively new approach in genetic toxicology, this report describes how AOPs could be harnessed to advance MOA analysis of genotoxicity pathways using five example case studies. Each of these genetic toxicology AOPs proposed for further development includes the relevant molecular initiating events, key events, and adverse outcomes (AOs), identification and/or further development of the appropriate assays to link an agent to these events, and discussion regarding the biological plausibility of the proposed AOP. A key difference between these proposed genetic toxicology AOPs versus traditional AOPs is that the AO is a genetic toxicology endpoint of potential significance in risk characterization, in contrast to an adverse state of an organism or a population. The first two detailed case studies describe provisional AOPs for aurora kinase inhibition and tubulin binding, leading to the common AO of aneuploidy. The remaining three case studies highlight provisional AOPs that lead to chromosome breakage or mutation via indirect DNA interaction (inhibition of topoisomerase II, production of cellular reactive oxygen species, and inhibition of DNA synthesis). These case studies serve as starting points for genotoxicity AOPs that could ultimately be published and utilized by the broader toxicology community and illustrate the practical considerations and evidence required to formalize such AOPs so that they may be applied to genetic toxicity evaluation schemes. Environ. Mol. Mutagen. 61:114–134, 2020. © 2019 Wiley Periodicals, Inc. 相似文献
2.
3.
David Jiménez Castro Gema Díaz David Martí Carlos Escobar Javier Ortega Sergio García-Rull Joaquin Picher Antonio Sueiro 《Blood coagulation & fibrinolysis》2007,18(2):173-177
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization. 相似文献
4.
5.
6.
7.
8.
R B Elliott L C Escobar H R Lees R M Akroyd H C Reilly 《The New Zealand medical journal》1992,105(930):107-108
OBJECTIVES: to compare the efficacy and tolerance of Creon and Pancrease in children and young adults with cystic fibrosis. METHODS: a double blind, crossover study of two pH sensitive microsphere preparations of pancreatin (Creon, Pancrease), given in equivalent lipase dosage to 27 children with cystic fibrosis, was conducted. RESULTS: at similar lipase activity no significant difference was found in the following: coefficient of fat absorption (CFA), coefficient of nitrogen absorption (CNA), weight gain, mean adequate daily intake for energy, and subjective symptoms. Three children who had a CFA less than 70% while receiving Pancrease all improved on Creon. No children had a CFA less than 70% while receiving Creon. A significant reduction in the number of capsules required daily to achieve similar control was possible when changing from Pancrease (mean 25/day) to Creon (mean 15/day). Seventy percent of patients preferred Creon and this was likely to be related to a perceived reduction in abdominal pain and stool frequency, and need for less capsules per day. CONCLUSION: Creon and Pancrease are equally effective at doses providing equal lipase activity, however, the reduced number of capsules, fewer symptoms, and possible improvement of more severe steatorrhoea result in an increased patient preference for Creon. 相似文献
9.
GP SCHWAB AL BLUM E BODNER B DALLEMAGNE K GLASER H KOOP F PACE W RÖSCH JR SIEWERT G WETSCHER 《Journal of gastroenterology and hepatology》1997,12(12):785-789
Gastroesophageal reflux disease (GERD) is the most common disease of the upper gastrointestinal tract. With the introduction of proton pump inhibitors medical treatment of GERD has been significantly improved. However, the development of laparoscopic antireflux surgery resulted in an increasing interest of surgeons in this disease. An interactive meeting was organized in order to develop an agreement between gastoenterologists and surgeons regarding therapeutic decisions and this is the main topic of this paper. 相似文献
10.